Sotera Health Company (NASDAQ: SHC) Stock Competitors & Peer Comparison
See SHC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SHC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SHC | $18.37 | +0.60% | 5.2B | 19.14 | $0.96 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.72% |
| TMO | $609.82 | +1.10% | 226.6B | 26.33 | $23.16 | +0.29% |
| DHR | $200.14 | -0.19% | 140.7B | 25.07 | $7.98 | +0.72% |
| NTRA | $328.93 | +0.86% | 47.1B | -249.19 | -$1.32 | N/A |
| IQV | $261.77 | +1.74% | 43.1B | 21.58 | $12.13 | N/A |
| A | $146.93 | +2.66% | 41.5B | 25.29 | $5.81 | +0.69% |
| IDXX | $504.70 | -0.36% | 39.8B | 35.49 | $14.22 | N/A |
| ILMN | $206.45 | +2.57% | 31.2B | 41.04 | $5.03 | N/A |
| WAT | $408.34 | +1.67% | 30.5B | 29.85 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
SHC vs DHR-PB Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, SHC's ROE is +0.27%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, SHC is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for SHC.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
SHC vs TMO Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, TMO has a market cap of 226.6B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while TMO trades at $609.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas TMO's P/E ratio is 26.33. In terms of profitability, SHC's ROE is +0.27%, compared to TMO's ROE of +0.13%. Regarding short-term risk, SHC is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for SHC.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
SHC vs DHR Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, DHR has a market cap of 140.7B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while DHR trades at $200.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas DHR's P/E ratio is 25.07. In terms of profitability, SHC's ROE is +0.27%, compared to DHR's ROE of +0.08%. Regarding short-term risk, SHC is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for SHC.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
SHC vs NTRA Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, NTRA has a market cap of 47.1B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while NTRA trades at $328.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas NTRA's P/E ratio is -249.19. In terms of profitability, SHC's ROE is +0.27%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, SHC is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for SHC.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
SHC vs IQV Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, IQV has a market cap of 43.1B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while IQV trades at $261.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas IQV's P/E ratio is 21.58. In terms of profitability, SHC's ROE is +0.27%, compared to IQV's ROE of +0.22%. Regarding short-term risk, SHC is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for SHC.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
SHC vs A Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, A has a market cap of 41.5B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while A trades at $146.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas A's P/E ratio is 25.29. In terms of profitability, SHC's ROE is +0.27%, compared to A's ROE of +0.20%. Regarding short-term risk, SHC is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for SHC.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
SHC vs IDXX Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, IDXX has a market cap of 39.8B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while IDXX trades at $504.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas IDXX's P/E ratio is 35.49. In terms of profitability, SHC's ROE is +0.27%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, SHC is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for SHC.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
SHC vs ILMN Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, ILMN has a market cap of 31.2B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while ILMN trades at $206.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas ILMN's P/E ratio is 41.04. In terms of profitability, SHC's ROE is +0.27%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, SHC is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for SHC.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
SHC vs WAT Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, WAT has a market cap of 30.5B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while WAT trades at $408.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas WAT's P/E ratio is 29.85. In terms of profitability, SHC's ROE is +0.27%, compared to WAT's ROE of +0.02%. Regarding short-term risk, SHC is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for SHC.Check WAT's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
SHC vs MTD Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, MTD has a market cap of 26.1B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while MTD trades at $1,293.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas MTD's P/E ratio is 29.73. In terms of profitability, SHC's ROE is +0.27%, compared to MTD's ROE of -12.00%. Regarding short-term risk, SHC is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for SHC.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
SHC vs DGX Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, DGX has a market cap of 25.9B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while DGX trades at $235.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas DGX's P/E ratio is 23.18. In terms of profitability, SHC's ROE is +0.27%, compared to DGX's ROE of +0.14%. Regarding short-term risk, SHC is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for SHC.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
SHC vs LH Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, LH has a market cap of 25.6B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while LH trades at $311.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas LH's P/E ratio is 18.49. In terms of profitability, SHC's ROE is +0.27%, compared to LH's ROE of +0.12%. Regarding short-term risk, SHC is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for SHC.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
SHC vs GH Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, GH has a market cap of 21.1B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while GH trades at $157.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas GH's P/E ratio is -45.09. In terms of profitability, SHC's ROE is +0.27%, compared to GH's ROE of +2.11%. Regarding short-term risk, SHC is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for SHC.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
SHC vs EXAS Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas EXAS's P/E ratio is -95.37. In terms of profitability, SHC's ROE is +0.27%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, SHC is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for SHC.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
SHC vs ILMNV Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas ILMNV's P/E ratio is N/A. In terms of profitability, SHC's ROE is +0.27%, compared to ILMNV's ROE of N/A. Regarding short-term risk, SHC is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for SHC.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
SHC vs MEDP Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, MEDP has a market cap of 16.4B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while MEDP trades at $587.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas MEDP's P/E ratio is 34.44. In terms of profitability, SHC's ROE is +0.27%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, SHC is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for SHC.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
SHC vs PKI Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas PKI's P/E ratio is 41.45. In terms of profitability, SHC's ROE is +0.27%, compared to PKI's ROE of +0.03%. Regarding short-term risk, SHC is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for SHC.Check PKI's competition here
Revvity, Inc. (NYSE: RVTY)
SHC vs RVTY Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, RVTY has a market cap of 13.9B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while RVTY trades at $124.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas RVTY's P/E ratio is 23.25. In terms of profitability, SHC's ROE is +0.27%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, SHC is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for SHC.Check RVTY's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
SHC vs CRL Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, CRL has a market cap of 13.4B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while CRL trades at $278.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas CRL's P/E ratio is 28.11. In terms of profitability, SHC's ROE is +0.27%, compared to CRL's ROE of -0.08%. Regarding short-term risk, SHC is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for SHC.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
SHC vs ICLR Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, ICLR has a market cap of 13B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while ICLR trades at $169.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas ICLR's P/E ratio is 13.81. In terms of profitability, SHC's ROE is +0.27%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, SHC is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for SHC.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
SHC vs QGEN Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while QGEN trades at $42.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas QGEN's P/E ratio is 17.54. In terms of profitability, SHC's ROE is +0.27%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, SHC is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for SHC.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
SHC vs RDNT Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, RDNT has a market cap of 5.9B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while RDNT trades at $75.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas RDNT's P/E ratio is 164.11. In terms of profitability, SHC's ROE is +0.27%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, SHC is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for SHC.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
SHC vs BLLN Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, BLLN has a market cap of 4.5B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while BLLN trades at $98.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas BLLN's P/E ratio is 141.10. In terms of profitability, SHC's ROE is +0.27%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, SHC is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for SHC.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
SHC vs SYNH Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas SYNH's P/E ratio is 61.40. In terms of profitability, SHC's ROE is +0.27%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, SHC is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for SHC.Check SYNH's competition here
GRAIL Inc. (NASDAQ: GRAL)
SHC vs GRAL Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while GRAL trades at $76.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas GRAL's P/E ratio is -7.82. In terms of profitability, SHC's ROE is +0.27%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, SHC is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for SHC.Check GRAL's competition here
Veracyte, Inc. (NASDAQ: VCYT)
SHC vs VCYT Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while VCYT trades at $40.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas VCYT's P/E ratio is 20.43. In terms of profitability, SHC's ROE is +0.27%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, SHC is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for SHC.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
SHC vs OLK Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas OLK's P/E ratio is -96.59. In terms of profitability, SHC's ROE is +0.27%, compared to OLK's ROE of -0.07%. Regarding short-term risk, SHC is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for SHC.Check OLK's competition here
CareDx, Inc (NASDAQ: CDNA)
SHC vs CDNA Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, CDNA has a market cap of 2.6B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while CDNA trades at $50.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas CDNA's P/E ratio is 59.83. In terms of profitability, SHC's ROE is +0.27%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, SHC is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for SHC.Check CDNA's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
SHC vs WGS Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, WGS has a market cap of 2.5B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while WGS trades at $85.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas WGS's P/E ratio is 236.85. In terms of profitability, SHC's ROE is +0.27%, compared to WGS's ROE of -0.39%. Regarding short-term risk, SHC is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for SHC.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
SHC vs PSNL Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while PSNL trades at $16.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas PSNL's P/E ratio is -14.88. In terms of profitability, SHC's ROE is +0.27%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, SHC is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for SHC.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
SHC vs OPK Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while OPK trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas OPK's P/E ratio is -5.81. In terms of profitability, SHC's ROE is +0.27%, compared to OPK's ROE of -0.06%. Regarding short-term risk, SHC is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for SHC.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
SHC vs CSTL Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, CSTL has a market cap of 987.7M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while CSTL trades at $32.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas CSTL's P/E ratio is -48.98. In terms of profitability, SHC's ROE is +0.27%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, SHC is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for SHC.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
SHC vs FLGT Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, FLGT has a market cap of 580.8M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while FLGT trades at $20.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas FLGT's P/E ratio is 2045.00. In terms of profitability, SHC's ROE is +0.27%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, SHC is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for SHC.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
SHC vs GRALV Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas GRALV's P/E ratio is N/A. In terms of profitability, SHC's ROE is +0.27%, compared to GRALV's ROE of N/A. Regarding short-term risk, SHC is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for SHC.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
SHC vs NEO Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, NEO has a market cap of 445M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while NEO trades at $17.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas NEO's P/E ratio is 133.23. In terms of profitability, SHC's ROE is +0.27%, compared to NEO's ROE of -0.06%. Regarding short-term risk, SHC is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for SHC.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
SHC vs CO Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas CO's P/E ratio is 5.06. In terms of profitability, SHC's ROE is +0.27%, compared to CO's ROE of +0.11%. Regarding short-term risk, SHC is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for SHC.Check CO's competition here
Prenetics Global Limited (NASDAQ: PRENW)
SHC vs PRENW Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, PRENW has a market cap of 325.8M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas PRENW's P/E ratio is N/A. In terms of profitability, SHC's ROE is +0.27%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, SHC is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for SHC.Check PRENW's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
SHC vs MYGN Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, MYGN has a market cap of 323M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while MYGN trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas MYGN's P/E ratio is -26.31. In terms of profitability, SHC's ROE is +0.27%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, SHC is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for SHC.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
SHC vs FLDM Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas FLDM's P/E ratio is -4.74. In terms of profitability, SHC's ROE is +0.27%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, SHC is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for SHC.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
SHC vs BDSX Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, BDSX has a market cap of 219.5M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while BDSX trades at $26.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas BDSX's P/E ratio is -8.51. In terms of profitability, SHC's ROE is +0.27%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, SHC is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for SHC.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
SHC vs XGN Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, XGN has a market cap of 169.8M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while XGN trades at $7.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas XGN's P/E ratio is -8.68. In terms of profitability, SHC's ROE is +0.27%, compared to XGN's ROE of -1.22%. Regarding short-term risk, SHC is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for SHC.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
SHC vs IMDX Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, IMDX has a market cap of 135.6M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while IMDX trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas IMDX's P/E ratio is -2.82. In terms of profitability, SHC's ROE is +0.27%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, SHC is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for SHC.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
SHC vs GTH Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas GTH's P/E ratio is -1.11. In terms of profitability, SHC's ROE is +0.27%, compared to GTH's ROE of -1.01%. Regarding short-term risk, SHC is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for SHC.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
SHC vs GENE Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas GENE's P/E ratio is -38.25. In terms of profitability, SHC's ROE is +0.27%, compared to GENE's ROE of -1.85%. Regarding short-term risk, SHC is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for SHC.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
SHC vs SERA Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, SERA has a market cap of 76.4M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while SERA trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas SERA's P/E ratio is -3.08. In terms of profitability, SHC's ROE is +0.27%, compared to SERA's ROE of -0.47%. Regarding short-term risk, SHC is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for SHC.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
SHC vs PRPO Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, PRPO has a market cap of 48.7M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while PRPO trades at $27.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas PRPO's P/E ratio is -105.08. In terms of profitability, SHC's ROE is +0.27%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, SHC is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for SHC.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
SHC vs MDXH Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, MDXH has a market cap of 36.2M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while MDXH trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas MDXH's P/E ratio is -1.85. In terms of profitability, SHC's ROE is +0.27%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, SHC is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for SHC.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
SHC vs QUCY Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, QUCY has a market cap of 30.7M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while QUCY trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas QUCY's P/E ratio is -0.06. In terms of profitability, SHC's ROE is +0.27%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, SHC is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for SHC.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
SHC vs AKU Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas AKU's P/E ratio is -0.13. In terms of profitability, SHC's ROE is +0.27%, compared to AKU's ROE of -5.32%. Regarding short-term risk, SHC is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for SHC.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
SHC vs CEMI Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas CEMI's P/E ratio is -0.63. In terms of profitability, SHC's ROE is +0.27%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, SHC is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for SHC.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
SHC vs ENZ Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas ENZ's P/E ratio is -2.24. In terms of profitability, SHC's ROE is +0.27%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, SHC is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for SHC.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
SHC vs PMD Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas PMD's P/E ratio is -5.24. In terms of profitability, SHC's ROE is +0.27%, compared to PMD's ROE of -0.32%. Regarding short-term risk, SHC is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for SHC.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
SHC vs ME Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas ME's P/E ratio is -0.03. In terms of profitability, SHC's ROE is +0.27%, compared to ME's ROE of -42.03%. Regarding short-term risk, SHC is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for SHC.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
SHC vs MYNZ Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, SHC's ROE is +0.27%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, SHC is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for SHC.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
SHC vs BNR Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, BNR has a market cap of 12.8M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while BNR trades at $12.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas BNR's P/E ratio is -13.89. In terms of profitability, SHC's ROE is +0.27%, compared to BNR's ROE of -0.11%. Regarding short-term risk, SHC is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for SHC.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
SHC vs ADVB Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, ADVB has a market cap of 11.3M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while ADVB trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas ADVB's P/E ratio is -74.45. In terms of profitability, SHC's ROE is +0.27%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, SHC is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for SHC.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
SHC vs CHEK Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas CHEK's P/E ratio is -0.43. In terms of profitability, SHC's ROE is +0.27%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, SHC is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for SHC.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
SHC vs CNTG Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas CNTG's P/E ratio is -0.23. In terms of profitability, SHC's ROE is +0.27%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, SHC is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for SHC.Check CNTG's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
SHC vs BIAFW Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, BIAFW has a market cap of 8.5M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while BIAFW trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas BIAFW's P/E ratio is 0.90. In terms of profitability, SHC's ROE is +0.27%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, SHC is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for SHC.Check BIAFW's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
SHC vs APDN Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas APDN's P/E ratio is -0.10. In terms of profitability, SHC's ROE is +0.27%, compared to APDN's ROE of -7.23%. Regarding short-term risk, SHC is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for SHC.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
SHC vs NDRA Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, NDRA has a market cap of 7.2M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while NDRA trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas NDRA's P/E ratio is -0.73. In terms of profitability, SHC's ROE is +0.27%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, SHC is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for SHC.Check NDRA's competition here
Invitae Corporation (NYSE: NVTA)
SHC vs NVTA Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas NVTA's P/E ratio is -0.00. In terms of profitability, SHC's ROE is +0.27%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, SHC is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for SHC.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
SHC vs LMDX Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas LMDX's P/E ratio is -0.01. In terms of profitability, SHC's ROE is +0.27%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, SHC is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for SHC.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
SHC vs LMDXW Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, SHC's ROE is +0.27%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, SHC is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for SHC.Check LMDXW's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
SHC vs BIAF Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while BIAF trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas BIAF's P/E ratio is -0.93. In terms of profitability, SHC's ROE is +0.27%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, SHC is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for SHC.Check BIAF's competition here
DermTech, Inc. (NASDAQ: DMTK)
SHC vs DMTK Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas DMTK's P/E ratio is -0.04. In terms of profitability, SHC's ROE is +0.27%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, SHC is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for SHC.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
SHC vs NOTV Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas NOTV's P/E ratio is -0.03. In terms of profitability, SHC's ROE is +0.27%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, SHC is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for SHC.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
SHC vs SQL Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas SQL's P/E ratio is -0.40. In terms of profitability, SHC's ROE is +0.27%, compared to SQL's ROE of -30.46%. Regarding short-term risk, SHC is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for SHC.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
SHC vs AWH Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas AWH's P/E ratio is -0.09. In terms of profitability, SHC's ROE is +0.27%, compared to AWH's ROE of +1.62%. Regarding short-term risk, SHC is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for SHC.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
SHC vs HTGM Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas HTGM's P/E ratio is -0.03. In terms of profitability, SHC's ROE is +0.27%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, SHC is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for SHC.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
SHC vs BIOC Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas BIOC's P/E ratio is -0.01. In terms of profitability, SHC's ROE is +0.27%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, SHC is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for SHC.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
SHC vs ISPC Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, ISPC has a market cap of 204.1K. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while ISPC trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas ISPC's P/E ratio is -0.05. In terms of profitability, SHC's ROE is +0.27%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, SHC is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for SHC.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
SHC vs SQLLW Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, SHC's ROE is +0.27%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, SHC is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for SHC.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
SHC vs WGSWW Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, SHC's ROE is +0.27%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, SHC is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for SHC.Check WGSWW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
SHC vs BNGOW Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas BNGOW's P/E ratio is N/A. In terms of profitability, SHC's ROE is +0.27%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, SHC is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for SHC.Check BNGOW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
SHC vs PRXL Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas PRXL's P/E ratio is 42.97. In terms of profitability, SHC's ROE is +0.27%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, SHC is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for SHC.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
SHC vs NDRAW Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas NDRAW's P/E ratio is N/A. In terms of profitability, SHC's ROE is +0.27%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, SHC is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for SHC.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
SHC vs CHEKZ Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, SHC's ROE is +0.27%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, SHC is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for SHC.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
SHC vs MEUSW Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas MEUSW's P/E ratio is N/A. In terms of profitability, SHC's ROE is +0.27%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, SHC is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for SHC.Check MEUSW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
SHC vs OCDX Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas OCDX's P/E ratio is -42.28. In terms of profitability, SHC's ROE is +0.27%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, SHC is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for SHC.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
SHC vs DHR-PA Comparison September 2026
Sotera Health Company (NASDAQ: SHC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHC stands at 5.2B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, SHC is priced at $18.37 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHC currently has a P/E ratio of 19.14, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, SHC's ROE is +0.27%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, SHC is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for SHC.Check DHR-PA's competition here